UNSPSC 51162611: Butamirate

This classification denotes an antitussive agent with the molecular formula C18H29NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) M75MZG2236, chemically known as butyric acid, 2-phenyl-, 2-(2-(diethylamino)ethoxy)ethyl ester, citrate but more generally known as butamirate, which bears US NIH Compound Identifier 28891. Butamirate most often comes in base and citrate forms. European Medicines Agency schedules Butamirate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06000MIG.

UNSPSC 51162611 Butamirate is a Commodity code that in recent state and local procurement activity covers pharmaceutical products including naloxone, generic multi-source pharmaceuticals, and over-the-counter medications supplied through authorized distribution channels to public health agencies and multi-state cooperative purchasing vehicles. The issuing bodies soliciting under this code include county health departments and state-led cooperative purchasing alliances; Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, have posted solicitations within the past six months. Work being solicited ranges from direct county procurement of naloxone and drug deactivation systems to broad manufacturer contracts for generic pharmaceuticals and OTC products distributed across multiple state and local government facilities through authorized wholesalers.

Recent activity spans Florida and Minnesota, with the MMCAP solicitation extending to participating states including Oregon. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking annual procurement of 1,900 units of naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries to the Seminole County Community Health Building in Sanford; the bid response deadline was July 26, 2023. MMCAP issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026; awarded vendors will be made available to authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC) by May 15, 2026, with contracts effective July 1, 2026. The MMCAP RFP weights price competitiveness at 75 percent of the evaluation and requires vendors to comply with cGMP, the Drug Supply Chain Security Act, and FDA requirements, with a two-year initial term and optional extensions.